Ruthenium Complexes as Protein Kinase Inhibitors

Organic Letters

Volumn 6, Issue 4, 2004, Pages 521-523

  Zhang, Lilu ^a   Carroll, Patrick ^a   Meggers, Eric ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPYRIDINE DERIVATIVE; CARBAZOLE DERIVATIVE; CARBOXYL GROUP; INDOLOCARBAZOLE; METHYL GROUP; PROTEIN KINASE INHIBITOR; RUTHENIUM COMPLEX; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG SYNTHESIS; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

CARBAZOLES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; INDOLES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RUTHENIUM; STAUROSPORINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1342311501     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol036283s     Document Type: Article

References (26)

1. Metal-based drugs: (a) Orvig, C.; Abrams, M. J. Chem. Rev. 1999, 99, 2201-2842. (b) Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38, 1512-1531.
2. Metal-based drugs: (a) Orvig, C.; Abrams, M. J. Chem. Rev. 1999, 99, 2201-2842. (b) Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38, 1512-1531.
3. (c) Farrell, N. Coord. Chem. Rev. 2002, 232, 1-230.
4. Metal ions and metal complexes as enzyme inhibitors: Louie, A. Y.; Meade, T. J. Chem. Rev. 1999, 99, 2711-2734.
5. (a) Sakai, S.; Shigemasa, Y.; Sasaki, T. Tetrahedron Lett. 1997, 38, 8145-8148.
6. (b) Takeuchi, T.; Böttcher, A.; Quezada, C. M.; Simon, M. I.; Meade, T. J.; Gray, H. B. J. Am. Chem. Soc. 1998, 120, 8555-8556.
7. (c) Lebon, F.; deRosny, E.; Reboud-Ravauz, M.; Durant, F. Eur. J. Med. Chem. 1998, 33, 733-737.
8. (d) Goral, V.; Nelen, M. I.; Eliseev, A. V.; Lehn, J.-M. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1347-1352.
9. (e) Liang, X.; Parkinson, J. A.; Weishäupl, M.; Gould, R. O.; Paisey, S. J.; Park, H.; Hunter, T. M.; Blindauer, C. A.; Parsons, S.; Sadler, P. J. J. Am. Chem. Soc. 2002, 124, 9105-9112.
10. Role of protein kinases in disease: (a) Hunter, T. Cell 2000, 100, 113-127. (b) Blume-Jensen, P.; Hunter, T. Nature 2001, 411, 355-365.
11. Role of protein kinases in disease: (a) Hunter, T. Cell 2000, 100, 113-127. (b) Blume-Jensen, P.; Hunter, T. Nature 2001, 411, 355-365.
12. Protein kinase inhibitors: (a) García-Echeverría, C.; Traxler, P.; Evans, D. B. Med. Res. Rev. 2000, 20, 28-57. (b) Cohen, P. Nature Rev. Drug Discov. 2002, 1, 309-315. (c) Cole, P. A.; Courtney, A. D.; Shen, K.; Zhang, Z.; Qiao, Y.; Lu, W.; Williams, D. M. Acc. Chem. Res. 2003, 36, 444-452.
13. Protein kinase inhibitors: (a) García-Echeverría, C.; Traxler, P.; Evans, D. B. Med. Res. Rev. 2000, 20, 28-57. (b) Cohen, P. Nature Rev. Drug Discov. 2002, 1, 309-315. (c) Cole, P. A.; Courtney, A. D.; Shen, K.; Zhang, Z.; Qiao, Y.; Lu, W.; Williams, D. M. Acc. Chem. Res. 2003, 36, 444-452.
14. Protein kinase inhibitors: (a) García-Echeverría, C.; Traxler, P.; Evans, D. B. Med. Res. Rev. 2000, 20, 28-57. (b) Cohen, P. Nature Rev. Drug Discov. 2002, 1, 309-315. (c) Cole, P. A.; Courtney, A. D.; Shen, K.; Zhang, Z.; Qiao, Y.; Lu, W.; Williams, D. M. Acc. Chem. Res. 2003, 36, 444-452.
15. See also: (a) Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Hernan Espinoza, F.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Science 2000, 281, 533-538. (b) Maly, D. J.; Choong, I. C.; Ellman, J. A. Proc. Natl. Acad. Sci 2000, 97, 2419-2424. (c) Bishop, A. C.; Buzko, O.; Shokat, K. M. Trends Cell Biol. 2001, 11, 167-172.
16. See also: (a) Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Hernan Espinoza, F.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Science 2000, 281, 533-538. (b) Maly, D. J.; Choong, I. C.; Ellman, J. A. Proc. Natl. Acad. Sci 2000, 97, 2419-2424. (c) Bishop, A. C.; Buzko, O.; Shokat, K. M. Trends Cell Biol. 2001, 11, 167-172.
17. See also: (a) Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Hernan Espinoza, F.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Science 2000, 281, 533-538. (b) Maly, D. J.; Choong, I. C.; Ellman, J. A. Proc. Natl. Acad. Sci 2000, 97, 2419-2424. (c) Bishop, A. C.; Buzko, O.; Shokat, K. M. Trends Cell Biol. 2001, 11, 167-172.
18. (a) Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. Biochem. Biophys. Res. Commun. 1986, 135, 397-402.
19. (b) Caravatti, G.; Meyer, T.; Fredenhagen, A.; Trinks, U.; Mett, H.; Fabbro, D. Bioorg. Med. Chem. Lett. 1994, 4, 399-404.
20. Toledo, L. M.; Lydon, N. B. Structure 1997, 5, 1551-1556.
21. This method was originally reported for the reductive cleavage of an α-keto acetate: Woodward, R. B.; Sondheimer, F.; Taub, D.; Heusler, K.; McLamore, W. M. J. Am. Chem. Soc. 1952, 74, 4223-4251.
22. Hargrave, K. D.; Proudfoot, H. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C. ; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. J. Med. Chem. 1991, 34, 2231-2241.
23. Stability of ruthenium complexes with 3 and 4 is coupled to the electronic nature of the other ligands. Ligand 3 seems to prefer an electron-rich center, whereas 4 prefers a more electron-poor ruthenium center.
24. Noncompetitive inhibition of PKC with respect to ATP has been reported for adriamycin-Fe(III) and anthracycline-Cu(II) complexes: (a) Hannun, Y. A.; Foglesong, R. J.; Bell, R. M. J. Biol. Chem. 1989, 264, 9960-9966. (b) Monti, E.; Monzini, F.; Morazzoni, F.; Perletti, G.; Piccinini, F. Inorg. Chim. Acta 1993, 205, 181-184.
25. Noncompetitive inhibition of PKC with respect to ATP has been reported for adriamycin-Fe(III) and anthracycline-Cu(II) complexes: (a) Hannun, Y. A.; Foglesong, R. J.; Bell, R. M. J. Biol. Chem. 1989, 264, 9960-9966. (b) Monti, E.; Monzini, F.; Morazzoni, F.; Perletti, G.; Piccinini, F. Inorg. Chim. Acta 1993, 205, 181-184.
26. Abl as a drug target: Nimmanapalli, R.; Bhalla, K. Oncogene 2002, 21, 8584-8590.